GO
Loading...

Elan Corporation PLC

More

  • Contest Leadearboard: Taft Still On Top Friday, 23 Mar 2007 | 9:04 AM ET

    Good morning. Deborah Taft stays in the top position with a portfolio value of $2,187,663.68 for a gain of $2,000.00 or 0.09% from Thursday's action. Deborah was all in cash and received $2,000 in bonus bucks and has put the majority of her holdings into Elan Corp. plc (ELN) as of 3/22. (those bonus bucks from the trivia questions do add up!!)

  • Elan reported a smaller fourth-quarter loss and higher sales Tuesday, citing the expansion of its multiple sclerosis-fighting drug Tysabri as a major factor.

  • First Tysabri, Now Rituxan Tuesday, 19 Dec 2006 | 1:33 PM ET

    The same rare, but fatal viral infection that forced Biogen Idec and Elan to recall, and recently relaunch, the multiple sclerosis drug, Tysabri, may also be a side effect of Rituxan, also from Biogen Idec and Genentech. In an SEC filing -- not a press release -- and on the FDA website, the companies and the agency disclosed yesterday evening that two people with lupus died after taking Rituxan.